LH
+0.0 · +0.00%
USD · NYSE

Laboratory Corporation of America Holdings(LH) Stock Analysis | Healthcare

USD --+0.00%
Reward41Moderate
Risk45Moderate
75%Data
Value Trap
Market Cap:27.18Bn
ⓘ
Reward Rating
41
Moderate
Reward Assessment
75% data coverage
Bottom 10% of stocksView factors
ⓘ
Risk Rating
45
Moderate
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LH to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for LH, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $341.50.

What is Laboratory Corporation of America Holdings?

It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments.

LH · Verdict

Moderate reward · moderate risk

LH's standout is cash flow; growth and profitability weigh on the picture.

Based on 88% data coverage

LH · Verdict

What’s working & what to watch

Strengths 1

  • Cash flow72/100

    9% free-cash-flow margin

Watchouts 2

  • Growth36/100

    Rev +5.6% CAGR · earnings -11.8%

  • Profitability36/100

    6% net margin · 12% ROE

Model-based scoring. For information only — not financial advice.

What is Laboratory Corporation of America Holdings?

It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 27.18B, and a P/E ratio of 27.7x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Discount reflects uncertainty around future performance.

OpenBook Logo Analysis

Reward: Moderate (41)

The scoring profile indicates limited reward potential at this time, with momentum and size offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Diagnostics & Research names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDiagnostics & Research
Market Cap27.18B
P/E Ratio27.7409
Dividend Yield0.86%
Beta0.843
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
18,705 shares
$2.4M
0
6-9months
47,408 shares
$2.1M
0
9-12months
212,754 shares
$3.3M
0